Skip to main content

Table 2 Factors associated with VR* at week 96 in total NAs-treated patients

From: Effectiveness of antiviral treatment in HBeAg-negative chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase: a retrospective study

Variable

Univariate analysis

Multivariate analysis

HR (95.0% CI)

p value

HR (95.0% CI)

p value

Age

1.002 (0.982–1.021)

0.892

  

Male (sex)

0.823 (0.549–1.255)

0.366

  

Baseline ALT(U/L)

0.994 (0.986–1.002)

0.120

  

Baseline AST(U/L)

0.993 (0.983–1.004)

0.209

  

HBV DNA (log10IU/mL)

 Baseline

0.774 (0.710–0.845)

< 0.001

0.893 (0.780–1.023)

0.104

 12 week

0.569 (0.487–0.665)

< 0.001

0.676 (0.560–0.817)

< 0.001

HBsAg (log10IU/mL)

 Baseline

0.657 (0.555–0.778)

< 0.001

1.004 (0.688–1.465)

0.985

 24 week

0.568 (0.470–0.686)

< 0.001

0.672 (0.485–0.931)

0.017

  1. *Defined as undetectable HBV DNA by sensitive PCR assay during the treatment and follow-up period. NAs, nucleoside/nucleotide analogues; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; HBV, Hepatitis B virus; HBsAg, hepatitis B surface antigen; HR, Hazard ratio; CI, Confidence interval
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us